ValuEngine Lowers AcelRx Pharmaceuticals, Inc. (ACRX) to Sell

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Tuesday, August 1st.

ACRX has been the topic of a number of other research reports. Zacks Investment Research raised shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a report on Wednesday, May 3rd. Piper Jaffray Companies set a $3.00 price objective on shares of AcelRx Pharmaceuticals and gave the company a “hold” rating in a research note on Tuesday, July 25th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $7.00 price objective on shares of AcelRx Pharmaceuticals in a research note on Friday, July 14th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $7.50.

AcelRx Pharmaceuticals (NASDAQ:ACRX) traded down 1.67% during trading on Tuesday, hitting $2.95. The stock had a trading volume of 468,777 shares. AcelRx Pharmaceuticals has a 1-year low of $1.95 and a 1-year high of $4.08. The stock’s market cap is $133.87 million. The firm’s 50-day moving average price is $2.89 and its 200-day moving average price is $2.79.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last announced its earnings results on Tuesday, August 1st. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.28) by $0.01. AcelRx Pharmaceuticals had a negative return on equity of 478.66% and a negative net margin of 319.19%. The business had revenue of $2.66 million for the quarter, compared to analyst estimates of $2.63 million. On average, equities research analysts predict that AcelRx Pharmaceuticals will post ($1.13) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “ValuEngine Lowers AcelRx Pharmaceuticals, Inc. (ACRX) to Sell” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at https://www.com-unik.info/2017/08/19/acelrx-pharmaceuticals-inc-acrx-downgraded-by-valuengine-to-sell-updated-updated.html.

In other news, major shareholder Life Sciences Maste Perceptive sold 875,000 shares of the stock in a transaction on Monday, June 19th. The shares were sold at an average price of $2.40, for a total transaction of $2,100,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 28.10% of the company’s stock.

Large investors have recently bought and sold shares of the company. ING Groep NV boosted its stake in AcelRx Pharmaceuticals by 200.0% in the first quarter. ING Groep NV now owns 39,000 shares of the specialty pharmaceutical company’s stock valued at $123,000 after buying an additional 26,000 shares during the period. Acadian Asset Management LLC boosted its stake in AcelRx Pharmaceuticals by 326.1% in the first quarter. Acadian Asset Management LLC now owns 41,927 shares of the specialty pharmaceutical company’s stock valued at $132,000 after buying an additional 32,087 shares during the period. Teachers Advisors LLC boosted its stake in AcelRx Pharmaceuticals by 14.6% in the fourth quarter. Teachers Advisors LLC now owns 66,715 shares of the specialty pharmaceutical company’s stock valued at $173,000 after buying an additional 8,475 shares during the period. Bank of New York Mellon Corp boosted its stake in AcelRx Pharmaceuticals by 6.6% in the first quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock valued at $355,000 after buying an additional 6,942 shares during the period. Finally, Virtu KCG Holdings LLC boosted its stake in AcelRx Pharmaceuticals by 600.9% in the second quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock valued at $255,000 after buying an additional 101,742 shares during the period. Institutional investors own 30.37% of the company’s stock.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for AcelRx Pharmaceuticals (NASDAQ:ACRX)

What are top analysts saying about AcelRx Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AcelRx Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit